SAN FRANCISCO, Jan. 23, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology
company focused on developing and commercializing gene therapy
products for patients living with serious, life-threatening rare
diseases, announced today that it intends to offer $150.0 million of its common stock in an
underwritten public offering. In addition, Audentes intends
to grant the underwriters a 30-day option to purchase up to an
additional $22.5 million of its
common stock offered in the public offering at the public offering
price less the underwriting discounts and commissions. All of
the shares will be offered and sold by Audentes. The offering
is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
BofA Merrill Lynch, Cowen and Leerink Partners are acting as
joint book-running managers for the offering. Wedbush PacGrow
is acting as co-manager.
The public offering will be made pursuant to a shelf
registration statement on Form S-3 that was filed by Audentes with
the Securities and Exchange Commission ("SEC") on August 8, 2017 and declared effective by the SEC
on August 23, 2017. A
preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC's website at www.sec.gov. A copy of the
preliminary prospectus relating to the offering may be obtained
from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street,
3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department or by email at
dg.prospectus_requests@baml.com; Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood,
NY 11717 or by telephone at (631) 274-2806; or Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, or
by email at syndicate@leerink.com, or by telephone at (800)
808-7525, ext. 6132.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein that do not
describe historical facts, including, but not limited to,
statements regarding the size and completion of the proposed
offering, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements. Such
risks and uncertainties include, among others, the risks identified
in Audentes' filings with the SEC, the prospectus related to the
offering, and subsequent filings with the SEC. Any of these
risks and uncertainties could materially and adversely affect
Audentes' results of operations, which would, in turn, have a
significant and adverse impact on Audentes' stock price.
Audentes cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. Audentes undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date they were made or to reflect
the occurrence of unanticipated events.
Audentes Contacts:
Investor Contact:
Andrew Chang, Investor Relations
415.818.1033
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-proposed-public-offering-of-common-stock-300586980.html
SOURCE Audentes Therapeutics, Inc.